IMUX Stock Analysis: Buy, Sell, or Hold?
IMUX - Immunic, Inc. Common Stock
$14.17
-0.47 (-3.21%)
▼
5d:
+1.21%
30d:
+33.43%
90d:
+1111.11%
HOLD
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When IMUX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called IMUX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IMUX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: IMUX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: IMUX is currently trading at $14.17, which is considered extended relative to its 30-day fair value range of $10.57 to $13.80.
Technical Outlook: Technically, IMUX is in a strong uptrend. Immediate support is located at $10.87, while resistance sits at $15.77. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.67 (+215.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IMUX is in a strong uptrend. Immediate support is located at $10.87, while resistance sits at $15.77. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.67 (+215.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.57 -
$13.80
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 215.2% below Wall St target ($44.67)
Trading Range Analysis
30-Day Trading Range
$10.57 -
$13.80
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.50
(17.6%)
Support & Resistance Levels
Support Level
$10.87
Resistance Level
$15.77
Current Trend
Strong Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.00
Wall Street Target
$44.67
(+215.2%)
Share & Embed Analysis
Last updated: June 04, 2026 5:29 AM ET
Data refreshes hourly during market hours. Next update: 6:29 AM
Data refreshes hourly during market hours. Next update: 6:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMUX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 54 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 52 HOLD |
